Walgreens announced the second step of the Alliance Boots transaction expected to close on 31 December 2014

NOTTINGHAM, UK, 2014-12-23 — /EPR Retail News/ — Alliance Boots notes that Walgreens has today announced that, subject to shareholder approval, the second step of the Alliance Boots transaction is expected to close on 31 December 2014, ahead of the original goal.

As previously disclosed, Walgreens will hold a special Meeting of shareholders on 29 December in New York City.

Walgreens shareholders will be asked to consider and vote upon the following items, among others:

  • the establishment of Walgreens Boots Alliance as the new publicly-traded holding company of the new combined enterprise, and
  • the issuance of Walgreens Boots Alliance shares

The transaction will fully combine the two companies to form the first global pharmacy-led, health and wellbeing enterprise.

ENDS

Notes to editors:

About Alliance Boots
Alliance Boots is a leading international pharmacy-led health and beauty group delivering a range of products and services to customers. Working in close partnership with manufacturers and pharmacists, we are committed to improving health in the local communities we serve and helping our customers and patients to look and feel their best. Our focus is on growing our two core business activities of: pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution, while increasingly developing and internationalising our product brands.

Alliance Boots has a presence in more than 26* countries and employs over 120,000* people. We have pharmacy-led health and beauty retail businesses in 10* countries and operate more than 4,550* health and beauty retail stores, of which just under 4,450* have a pharmacy, with a fast growing online presence. In addition, Alliance Boots has around 600* optical practices, of which around 180* operate on a franchise basis, and hearingcare services in around 430* locations. Our pharmaceutical wholesale businesses deliver over 4.3* billion units each year to more than 175,000* pharmacies, doctors, health centres and hospitals from over 340* distribution centres in 19* countries.

In June 2012, Alliance Boots announced that it had entered into a strategic partnership with Walgreen Co. (Walgreens), the largest drugstore chain in the US. In August 2014, Alliance Boots and Walgreens communicated that they plan to merge in the first quarter of calendar 2015 to create the first global pharmacy-led, health and wellbeing enterprise, which will be named Walgreens Boots Alliance.

* Figures are approximations as at 31 March 2014, with the addition of Farmacias Ahumada data at the date of its acquisition on 11 August 2014, and include associates and joint ventures.

For further information, please contact:

Media relations:

Yves Romestan/Laura Vergani/Katie Johnson/Julie Longton, Alliance Boots: +44 (0)207 980 8585

James Murgatroyd/Claire Scicluna, Finsbury: +44 (0)207 251 3801

Investor relations:

Gerald Gradwell, Alliance Boots: +44 (0)207 980 8527 (UK)/+1 646 688 1336 (US)

Walgreens President and CEO Greg Wasson to retire after the close of the second step of the Alliance Boots transaction

  • Upon transaction close, Chairman James Skinner to become Executive Chairman of Walgreens Boots Alliance and Stefano Pessina, Executive Chairman of Alliance Boots, to serve as Acting CEO, pending board search for successor
  • William Foote will serve as the lead independent director of the Walgreens Boots Alliance board of directors

DEERFIELD, Ill., 2014-12-11 — /EPR Retail News/ — Walgreens (NYSE: WAG) (Nasdaq: WAG) today announced that Greg Wasson, president and chief executive officer, has informed the company’s board of directors that he will retire shortly after the close of the second step of the Alliance Boots transaction, on which shareholders are scheduled to vote on Dec. 29, 2014. Following the transaction close and Wasson’s retirement, Walgreens Chairman James Skinner will become Walgreens Boots Alliance’s executive chairman, and Stefano Pessina, executive chairman of Alliance Boots and a member of the Walgreens board of directors, will serve as its acting CEO, pending a board search for a successor. In addition, William Foote will serve as the lead independent director of the Walgreens Boots Alliance board of directors.

“When I became CEO six years ago, I had three goals – to transform the front end of Walgreens drugstores, to advance the role that community pharmacy plays in health care and to find the right partner to take Walgreens global,” Wasson said. “With the creation of Walgreens Boots Alliance, it is now time for new leadership to move that vision forward building on the global platform we have created, executing on the company’s many opportunities and creating long-term sustainable value for our customers and shareholders. I could not be more proud of our company or more grateful for the opportunities I have had to work with so many incredible people since joining Walgreens over 35 years ago, and I am committed to doing my best to achieve the smoothest possible leadership transition.”

Said Skinner, “Greg Wasson has been an excellent, visionary CEO, and the personification of Walgreens best qualities since he joined the company 35 years ago. On becoming CEO in 2009, at a challenging time for all retailers, Greg led the company through a remarkable transformation, including establishing Walgreens as a vital partner in the delivery of modern community health care to U.S. consumers and taking the company global with Alliance Boots. During his tenure, he helped the company deliver total shareholder returns exceeding the S&P 500 and generating more free cash flow over six years than in the previous 98 years combined. The company is positioned for a great future. On behalf of the board, I thank Greg for all he has done for Walgreens, for his commitment to seeing us through the Alliance Boots close and for his dedication to always putting the company first.”

Pessina said, “The completion of the merger between Walgreens and Alliance Boots and the establishment of the first global pharmacy-led, health and wellbeing enterprise, are a fitting tribute to Greg’s exceptional leadership and legacy at Walgreens. Through his strategic vision, Greg has done more than transform an iconic company – he has truly helped to change an entire industry for generations to come. I look forward to working with James Skinner and all the leaders of the future enterprise when we launch the combined group.”

Wasson joined Walgreens in 1980 as a pharmacy intern while still at Purdue University’s School of Pharmacy. Over several years, he moved from managing pharmacies in Houston to become regional vice president of store operations. From there he took on various executive roles in the Walgreens Health Initiatives division, leading to his promotion to chief operating officer and ultimately to chief executive officer. On becoming CEO, Wasson focused immediately on tackling retail pharmacy’s challenges, from the severe economic recession, to the rapid commoditization of retail consumer sales and pharmacy services, to rising drug prices and mounting reimbursement pressures. He launched “Walgreens Plan to Win,” a blueprint designed to revive and reinvent Walgreens for the new era. “Plan to Win” transitioned the company from a program of rapid organic store openings to a strategy leveraging core businesses to improve the customer experience and return the company to strong double-digit earnings growth and top-tier shareholder returns. The company crystallized around three strategic growth drivers: creating a Well Experience, advancing the role of community pharmacy in health care and establishing the most efficient global platform. In 2010, he led the acquisition of Duane Reade and, in 2012, identified the opportunity to begin the process of the strategic partnership with Alliance Boots.

In addition to Walgreens, Wasson is on the boards of Alliance Boots GmbH, AmerisourceBergen and Verizon.

About Walgreens
As the nation’s largest drugstore chain with fiscal 2014 sales of $76 billion, Walgreens (www.walgreens.com) vision is to be America’s most loved pharmacy-led health, wellbeing and beauty enterprise. Each day, in communities across America, more than 8 million customers interact with Walgreens using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice. Walgreens scope of pharmacy services includes retail, specialty, infusion, medical facility and mail service, along with online and mobile services. These services improve health outcomes and lower costs for payers including employers, managed care organizations, health systems, pharmacy benefit managers and the public sector. The company operates 8,229 drugstores with a presence in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands. Walgreens digital business includes Walgreens.com, drugstore.com, Beauty.com, SkinStore.com and VisionDirect.com. Walgreens also manages more than 400 Healthcare Clinic and provider practice locations around the country.

Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements: Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,” “will,” “project,” “intend,” “plan,” “goal,” “target,” “continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, those described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K, as amended, which is incorporated herein by reference, and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, Walgreens does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

Important Information for Investors and Shareholders

In connection with the proposed transactions between Walgreens and Alliance Boots GmbH, Walgreens Boots Alliance, Inc. (“WBA”) has filed with the SEC a registration statement on Form S-4 and two amendments thereto, as well as a definitive prospectus of WBA and a definitive proxy statement of Walgreens in connection with the proposed transactions. The registration statement, as amended, was declared effective by the Securities and Exchange Commission (the “SEC”) on November 24, 2014, and the definitive proxy statement/prospectus was mailed to Walgreens’ shareholders on or about November 24, 2014. INVESTORS AND SECURITY HOLDERS OF WALGREENS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE TRANSACTIONS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Investors and security holders will be able to obtain free copies of the registration statement and the definitive proxy statement/prospectus and other documents filed with the SEC by Walgreens or WBA through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Walgreens or WBA will be available free of charge on Walgreens’ internet website atwww.walgreens.com under the heading “Investor Relations” and then under the heading “SEC Filings” or by contacting Walgreens’ Investor Relations Department at (847) 315-2361.

Participants in the Solicitation

Walgreens, Alliance Boots GmbH, WBA and their respective directors, executive officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies from the holders of Walgreens common stock in respect of the proposed transactions. You can find information about Walgreens’ directors and executive officers in Walgreens’ Annual Report on Form 10-K for the year ended August 31, 2014, as amended. Additional information regarding the persons who are, under the rules of the SEC, participants in the solicitation of proxies in favor of the proposed transactions is set forth in the definitive proxy statement/prospectus. You can obtain free copies of these documents, which are filed with the SEC, from Walgreens using the contact information above.

Contact(s)

Walgreens
Michael Polzin
847-315-2920
http://news.walgreens.com
@WalgreensNews
facebook.com/Walgreens

Alliance Boots announces that it has completed the acquisition of 12% stake in Nanjing Pharmaceutical Company Limited in China

Nottingham, UK, 2014-12-4 — /EPR Retail News/ — Alliance Boots today announces that it has completed the acquisition of a 12% stake in Nanjing Pharmaceutical Company Limited.

The completion follows receipt of government and regulatory approvals. As a result of the investment, Alliance Boots becomes the second largest shareholder of the company with the right to nominate Board members and a member of the senior management.

In September 2012, Alliance Boots announced its intention to invest in Nanjing Pharmaceutical Company Limited through a private placement, for a total consideration of approximately £56 million (RMB560 million).

Alliance Boots first entered the Chinese market in 2008 through its joint venture, Guangzhou Pharmaceuticals Corporation, which operates in complementary geographies and continues its successful development.

ENDS

Notes to editors:

About Nanjing Pharmaceutical Company Limited
Nanjing Pharmaceutical Company Limited is the seventh largest pharmaceutical wholesaler in China. It specialises in pharmaceutical wholesaling and distribution, with an additional network of nearly 300 branded community pharmacies. In recent years, it has focussed on the operation of in-hospital pharmacies with innovative services and supply chain solutions. The company operates primarily in East and Southeast China, with regional coverage including Jiangsu, Anhui and Fujian, as well as several central provinces.

At November 2014, Nanjing Pharmaceutical Company Limited employed more than 5,000 people. Its revenue in 2013 was around £2 billion (RMB20 billion). The company has been listed on the Shanghai Stock Exchange since 1996, when it was the first ever pharmaceutical wholesaler in China to become public.

About Alliance Boots
Alliance Boots is a leading international pharmacy-led health and beauty group delivering a range of products and services to customers. Working in close partnership with manufacturers and pharmacists, we are committed to improving health in the local communities we serve and helping our customers and patients to look and feel their best. Our focus is on growing our two core business activities of: pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution, while increasingly developing and internationalising our product brands.

Alliance Boots has a presence in more than 27* countries and employs over 120,000* people. We have pharmacy-led health and beauty retail businesses in 11* countries and operate more than 4,600* health and beauty retail stores, of which more than 4,450* have a pharmacy, with a fast growing online presence. In addition, Alliance Boots has around 600* optical practices, of which around 180* operate on a franchise basis, and hearingcare services in around 430* locations. Our pharmaceutical wholesale businesses deliver over 4.5* billion units each year to more than 180,000* pharmacies, doctors, health centres and hospitals from over 370* distribution centres in 20* countries.

In June 2012, Alliance Boots announced that it had entered into a strategic partnership with Walgreen Co. (Walgreens), the largest drugstore chain in the US. In August 2014, Alliance Boots and Walgreens communicated that they plan to merge in the first quarter of calendar 2015 to create the first global pharmacy-led, health and wellbeing enterprise, which will be named Walgreens Boots Alliance.

* Figures are approximations as at 31 March 2014, with the addition of Farmacias Ahumada data at the date of its acquisition on 11 August 2014, and include associates and joint ventures.

For further information, please contact:

Media relations:

Yves Romestan/Laura Vergani/Katie Johnson/Julie Longton, Alliance Boots: +44 (0)207 980 8585
James Murgatroyd/Claire Scicluna, RLM Finsbury: +44 (0)207 251 3801

Investor relations:

Gerald Gradwell, Alliance Boots: +44 (0)207 980 8527 (UK)/+1 646 688 1336 (US)

Alliance Boots announces that China Securities Regulatory Commission approved the Group’s investment in Nanjing Pharmaceutical Company Limited

Nottingham, 2014-9-30— /EPR Retail News/ — Alliance Boots announces that China Securities Regulatory Commission (CSRC) has approved the Group’s investment in Nanjing Pharmaceutical Company Limited. This approval, following the authorisation recently received from China Ministry of Commerce (MOFCOM), paves the way for the completion of the investment in the coming weeks. As a result of the investment, Alliance Boots will become the second largest shareholder in Nanjing Pharmaceutical Company Limited with Board and operational management representation.

In September 2012, Alliance Boots announced that it will acquire a 12% stake in Nanjing Pharmaceutical Company Limited, through a private placement, for a total consideration of approximately £56 million (RMB560 million). Nanjing Pharmaceutical Company Limited, listed on the Shanghai Stock Exchange, is the seventh largest pharmaceutical wholesaler in China with sales of around £2 billion (RMB20 billion) in 2013.

The Group first entered the Chinese market in 2008 through its joint venture Guangzhou Pharmaceuticals Corporation, which operates in complementary geographies and continues its successful development.

ENDS

Notes to editors:

About Alliance Boots
Alliance Boots is a leading international pharmacy-led health and beauty group delivering a range of products and services to customers. Working in close partnership with manufacturers and pharmacists, we are committed to improving health in the local communities we serve and helping our customers and patients to look and feel their best. Our focus is on growing our two core business activities of: pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution, while increasingly developing and internationalising our product brands.

Alliance Boots has a presence in more than 27* countries and employs over 120,000* people. We have pharmacy-led health and beauty retail businesses in 11* countries and operate more than 4,600* health and beauty retail stores, of which more than 4,450* have a pharmacy, with a fast growing online presence. In addition, Alliance Boots has around 600* optical practices, of which around 180* operate on a franchise basis, and hearingcare services in around 430* locations. Our pharmaceutical wholesale businesses deliver over 4.5* billion units each year to more than 180,000* pharmacies, doctors, health centres and hospitals from over 370* distribution centres in 20* countries.

In June 2012, Alliance Boots announced that it had entered into a strategic partnership with Walgreen Co. (Walgreens), the largest drugstore chain in the US. In August 2014, Alliance Boots and Walgreens communicated that they plan to merge in the first quarter of calendar 2015 to create the first global pharmacy-led, health and wellbeing enterprise, which will be named Walgreens Boots Alliance.

* Figures are approximations as at 31 March 2014, with the addition of Farmacias Ahumada data at the date of its acquisition on 11 August 2014, and include associates and joint ventures.

For further information, please contact:

Media relations:

Yves Romestan/ Laura Vergani / Katie Johnson / Julie Longton , Alliance Boots: +44 (0)207 980 8585
Claire Scicluna, RLM Finsbury: +44 (0)207 251 3801

Investor relations:

Gerald Gradwell, Alliance Boots: +44 (0)207 980 8527 (UK)/+1 646 688 1336 (US)

Alliance Boots publishes its Corporate Social Responsibility Report 2013/14 for the year ended 31 March 2014

Nottingham, 2014-9-22— /EPR Retail News/ — Alliance Boots today has published its Corporate Social Responsibility (CSR) Report 2013/14 for the year ended 31 March 2014.

The Group’s expanding global footprint provides opportunities to further its contribution towards a sustainable future. Working within the healthcare industry, Alliance Boots is in a privileged position to help improve the healthcare available to communities around the world by providing medicines, quality products and services, as well as expert advice to people every day.

CSR forms an integral part of Alliance Boots commercial philosophy and is at the heart of its efforts to serve communities with care and commitment. The Group recognises the importance of working in partnership and championing worthwhile causes, such as the fight against cancer. During the year, it has continued to support charitable partnerships, including the European Organisation for Research and Treatment of Cancer Charitable Trust and Macmillan Cancer Support in the UK, through a wide variety of fundraising activities and volunteering initiatives.

Alliance Boots understands the value that can be created through collaboration between academia and industry, and continues to work with highly regarded academic institutions. Such collaborations help to better inform its business activities, as well as generate benefits within the health and beauty industry for customers and patients.

Ornella Barra, Chairman of the social responsibilities committee, Alliance Boots, comments: “With an increasing presence across many communities around the world, we continue to recognise the importance of ensuring that our business practices are socially, environmentally and economically sustainable across the Group. Working in close partnership with our many stakeholders and inspiring our teams within the field of CSR has enabled us to succeed in becoming a leader within the responsibility agenda.”

As in previous years, this report includes an independent assurance report on the Group’s 2013/14 CSR data, issued by KPMG, which reinforces its established processes and procedures in relation to data capture and accuracy.

The report can be accessed online here: Alliance Boots CSR Report 2013/14

ENDS

Notes to editors:

About Alliance Boots
Alliance Boots is a leading international pharmacy-led health and beauty group delivering a range of products and services to customers. Working in close partnership with manufacturers and pharmacists, we are committed to improving health in the local communities we serve and helping our customers and patients to look and feel their best. Our focus is on growing our two core business activities of: pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution, while increasingly developing and internationalising our product brands.

Alliance Boots has a presence in more than 27* countries and employs over 120,000* people. We have pharmacy-led health and beauty retail businesses in 11* countries and operate more than 4,600* health and beauty retail stores, of which more than 4,450* have a pharmacy, with a fast growing online presence. In addition, Alliance Boots has around 600* optical practices, of which around 180* operate on a franchise basis, and hearingcare services in around 430* locations. Our pharmaceutical wholesale businesses deliver over 4.5* billion units each year to more than 180,000* pharmacies, doctors, health centres and hospitals from over 370* distribution centres in 20* countries.

In June 2012, Alliance Boots announced that it had entered into a strategic partnership with Walgreen Co. (Walgreens), the largest drugstore chain in the US. In August 2014, Alliance Boots and Walgreens communicated that they plan to merge in the first quarter of calendar 2015 to create the first global pharmacy-led, health and wellbeing enterprise, which will be named Walgreens Boots Alliance.

* Figures are approximations as at 31 March 2014, with the addition of Farmacias Ahumada data at the date of its acquisition on 11 August 2014, and include associates and joint ventures.

For further information, please contact:

Media relations:

Laura Vergani/Katie Johnson, Alliance Boots: +44 (0)207 980 8585
Claire Scicluna, RLM Finsbury: +44 (0)207 251 3801

Investor relations:

Gerald Gradwell, Alliance Boots: +44 (0)207 980 8527 (UK)/+1 646 688 1336 (US)